U.S. Could Speed Device Innovation Through Clinical Research Reforms
This article was originally published in The Gray Sheet
A focus on FDA regulations alone will not reverse the trend of device innovation efforts moving overseas, clinical investigators and regulators said last week at the Cardiovascular Research Technologies meeting in Washington, D.C.
You may also be interested in...
In granting IDE approval for a feasibility study of Medtronic’s Native Outflow Tract Transcatheter Pulmonary Valve, FDA followed a pathway laid out in a November 2011 draft guidance intended to streamline requirements for starting up and modifying early feasibility studies.
New FDA guidances aim to strike a balance by allowing firms to begin trials earlier through adaptive study designs, while ensuring that patients are adequately protected.
FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.